These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37154101)

  • 1. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
    Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
    Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
    Arjumand W; Asiaf A; Ahmad ST
    Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving DNA repair synthetic lethality targets in cancer.
    Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.
    Jurkovicova D; Neophytou CM; Gašparović AČ; Gonçalves AC
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA damage response for cancer therapy.
    Curtin NJ
    Biochem Soc Trans; 2023 Feb; 51(1):207-221. PubMed ID: 36606678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
    Xavier MA; Rezende F; Titze-de-Almeida R; Cornelissen B
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies.
    Bonm A; Kesari S
    Cancer J; 2021 Sep-Oct 01; 27(5):379-385. PubMed ID: 34570452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
    Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
    Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
    J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells.
    Yang WB; Wu AC; Hsu TI; Liou JP; Lo WL; Chang KY; Chen PY; Kikkawa U; Yang ST; Kao TJ; Chen RM; Chang WC; Ko CY; Chuang JY
    Cell Death Dis; 2021 Sep; 12(10):884. PubMed ID: 34584069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    Gulliver C; Hoffmann R; Baillie GS
    Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress.
    Kaur E; Ketkar M; Dutt S
    Med Oncol; 2022 Feb; 39(5):50. PubMed ID: 35150325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of DNA damage response inhibitors for the treatment of glioblastoma.
    Majd NK; Yap TA; Koul D; Balasubramaniyan V; Li X; Khan S; Gandy KS; Yung WKA; de Groot JF
    Neurooncol Adv; 2021; 3(1):vdab015. PubMed ID: 33738447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to DNA repair inhibitors in cancer.
    Baxter JS; Zatreanu D; Pettitt SJ; Lord CJ
    Mol Oncol; 2022 Nov; 16(21):3811-3827. PubMed ID: 35567571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic basis for PARP mutagenesis in glioblastoma: A review.
    M A; Xavier J; A S F; Bisht P; Murti K; Ravichandiran V; Kumar N
    Eur J Pharmacol; 2023 Jan; 938():175424. PubMed ID: 36442619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.